NCT02538510 2024-11-26Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by SurgeryUniversity of WashingtonPhase 1/2 Completed50 enrolled 13 charts
NCT01175980 2020-08-03Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic CarcinomaNational Cancer Institute (NCI)Phase 2 Completed30 enrolled 16 charts
NCT01064921 2019-06-04Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell CarcinomaOhio State University Comprehensive Cancer CenterPhase 1 Completed27 enrolled
NCT00735826 2018-10-12A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract CancerDartmouth-Hitchcock Medical CenterPhase NA Completed10 enrolled 7 charts
NCT00134043 2014-08-11Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerNational Cancer Institute (NCI)Phase 2 Completed19 enrolled 11 charts
NCT00045006 2013-05-30Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced CancerNational Cancer Institute (NCI)Phase 1 Completed